Apoptosis-Induced Stem Cells With IL-10 for DMSO-Free Cryopreservation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing stem cell therapeutic agents are sensitive to environmental conditions and have a short shelf life, and conventional cryoprotectants like DMSO cause cytotoxicity and immune responses, making them unsuitable for long-term preservation and administration.
Innovation Solution
Cryopreservation of stem cells without a cryoprotectant using a blood substitute solution, inducing apoptosis to increase IL-10 expression, resulting in cells with enhanced immune and anti-inflammatory properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cryoprotectants like DMSO are used for cryopreservation of stem cells, then cell preservation during freezing is improved, but cytotoxicity and immune responses are induced
Solution Approach 1:
The patent applies this principle by intentionally inducing apoptosis in stem cells before cryopreservation. The apoptotic cells, which would normally be considered damaged or useless, are converted into a therapeutic product with enhanced anti-inflammatory properties. The cryopreservation process is used not to preserve viable cells for transplantation, but to preserve apoptotic cells that have been engineered to secrete IL-10, transforming a harmful process (apoptosis) into a beneficial therapeutic mechanism
Solution Approach 2:
The patent changes the physiological state parameter of the stem cells from viable to apoptotic before cryopreservation. By inducing apoptosis through controlled methods (such as using apoptotic inducing agents or specific culture conditions), the cells undergo programmed death while maintaining their ability to secrete IL-10. This parameter change allows the cells to be cryopreserved without the cytotoxic effects of conventional cryoprotectants, as the apoptotic state makes them less sensitive to freezing damage
2Duration of action of stationary object
If stem cells are cryopreserved for long-term preservation, then shelf life is extended, but cell viability and therapeutic characteristics are compromised
Solution Approach 1:
The patent applies preliminary action by inducing apoptosis in the stem cells before the cryopreservation process. This pre-treatment ensures that the cells are in the desired apoptotic state before freezing, which prevents the need for long-term cryopreservation of viable cells. The cells are prepared in advance with the therapeutic特性 they need (apoptotic state with IL-10 secretion capability), and then cryopreserved in this stable state, extending shelf life without compromising the therapeutic mechanism
Solution Approach 2:
The patent treats the stem cells as disposable therapeutic agents that are cryopreserved in an apoptotic state rather than as viable cells meant for long-term culture and expansion. The cryopreserved apoptotic cells are designed to be administered directly without requiring post-thaw culture or viability verification, accepting the short-lived nature of the cells after thawing as part of the therapeutic mechanism rather than a limitation to be overcome
3Reliability
If apoptosis is induced in stem cells to increase IL-10 expression, then anti-inflammatory efficacy is improved, but cell survival rate decreases
Solution Approach 1:
The patent converts the harmful effect of apoptosis (cell death) into a beneficial therapeutic mechanism. By inducing controlled apoptosis, the cells upregulate IL-10 expression and acquire potent anti-inflammatory properties. The cell death itself becomes the therapeutic action, as the apoptotic cells and their secreted IL-10 provide the desired anti-inflammatory effect rather than cell survival
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The apoptosis-induced stem cells with increased IL-10 expression provide effective prevention and treatment of inflammatory and renal diseases without cytotoxicity, maintaining therapeutic efficacy and safety.
Implementation Method 1
a cell cryopreservation process is essential. During cell cryopreservation, cryoprotectants are generally used because cells are damaged by crystallization of ice within the cells
Implementation Method 2
apoptosis is a type of programmed cell death that can be seen in multicellular organisms. Apoptosis is cell death resulting from changes in cell morphology and internal biochemical changes
Data Source
AI summary
The present disclosure relates to apoptosis-induced stem cells, a method for producing the same, and a pharmaceutical composition for the prevention or treatment of an inflammatory disease or a renal disease, including the same. Cells according to an aspect and a composition including the cells as an active ingredient have an increased IL-10 expression level without including a cryoprotectant, and thus can be effectively used for the prevention or treatment of an inflammatory disease or a renal disease.